United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News AstraZeneca’s Imfinzi demonstrates significant survival benefits in Phase 3 ADRIATIC trial In a significant advancement for cancer treatment, AstraZeneca’s Imfinzi (durvalumab) has emerged as the first and only immunotherapy… byPallavi MadhirajuApril 7, 2024